Flag of the European Union EU Clinical Trials Register Help

Clinical trials for parkinson

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    443 result(s) found for: parkinson. Displaying page 8 of 23.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2016-000657-12 Sponsor Protocol Number: ACT14820 Start Date*: 2016-11-09
    Sponsor Name:Genzyme Corporation
    Full Title: Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients with Early-stage Parkinson's Disea...
    Medical condition: Parkinson's disease (PD) carrying a GBA mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Completed) AT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003490-27 Sponsor Protocol Number: 204PD202 Start Date*: 2006-12-19
    Sponsor Name:BIOGEN IDEC LTD
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Single and Multiple Oral Dose Administration of BIIB014 in Subjects with Moderate to Late Stage Parkinson’s Disease Who Are ...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-012897-12 Sponsor Protocol Number: BIA-91067-202 Start Date*: 2009-12-08
    Sponsor Name:BIAL-Portela & Ca, SA
    Full Title: A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyl...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-003869-72 Sponsor Protocol Number: BIA-91067-201 Start Date*: 2008-10-03
    Sponsor Name:Bial - Portela & Cª, S.A.
    Full Title: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, CROSS-OVER STUDY TO INVESTIGATE THE TOLERABILITY AND EFFECT OF THREE SINGLE-DOSE REGIMENS OF BIA 9-1067 ON THE LEVODOPA PHARMACOKINETICS, MOTOR RESPO...
    Medical condition: Parkinson
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003512-57 Sponsor Protocol Number: P 07-02/BF 2.649 Start Date*: 2007-08-24
    Sponsor Name:Bioprojet
    Full Title: Randomized, dose-finding study of BF 2.649 5, 10, 20 and 40 mg/d in comparison to placebo in Excessive Daytime Sleepiness in Parkinson’s Disease patients (PD)
    Medical condition: Excessive daytime sleepiness associated to Parkinson disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041014 Sleepiness LLT
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000826-89 Sponsor Protocol Number: 35RC21_9909_PHARM-APO Start Date*: 2021-04-23
    Sponsor Name:CHU Rennes
    Full Title: Etude pharmacocinétique de l’apomorphine en perfusion sous-cutanée continue diurne chez le patient parkinsonien équilibré sous traitement
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013552-72 Sponsor Protocol Number: P05664 Start Date*: 2010-09-07
    Sponsor Name:Schering-Plough Research Institute, a division of Schering Corporation
    Full Title: A Phase 3, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Dose-Range-Finding Efficacy and Safety Study of Preladenant in Subjects With Early Parkinson’s Disease (Phase 3 Protocol No. P0...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001403-23 Sponsor Protocol Number: M15-535 Start Date*: 2017-02-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects with ...
    Medical condition: Dyskinesia in advanced Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed) GR (Completed) ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005078-39 Sponsor Protocol Number: ND0612H-006 Start Date*: 2016-09-21
    Sponsor Name:NeuroDerm Ltd.
    Full Title: A multicenter, parallel-group, rater-blinded, randomized clinical study investigating the efficacy, safety, tolerability and pharmacokinetics of 2 dosing regimens of ND0612H, a solution of levodopa...
    Medical condition: Subjects with advanced Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001063-27 Sponsor Protocol Number: JZP385-202-01 Start Date*: 2023-07-19
    Sponsor Name:Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.
    Full Title: A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Seve...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-001329-33 Sponsor Protocol Number: S187.3.005 Start Date*: 2009-10-02
    Sponsor Name:AbbVie Inc
    Full Title: Open-Label Continuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuations Who Have Exhibited A Persistent And Posi...
    Medical condition: Treatment with Levodopa – Carbidopa Intestinal Gel in subjects with advanced Parkinson's disease and severe motor-fluctuations who have exhibited a persistent and positive effect to treatment in pr...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003732-30 Sponsor Protocol Number: NbT 01-06 / TULEP 1 Start Date*: 2007-01-31
    Sponsor Name:Axxonis Pharma AG
    Full Title: Transdermal Use of Lisuride in Early Parkinson´s Disease: A double blind, randomized, Placebo and Pramipexole controlled study to evaluate the efficacy and safety of Lisuride TTS
    Medical condition: Early Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006045-10 Sponsor Protocol Number: loc/08-08VerinAPOTEP Start Date*: 2009-02-06
    Sponsor Name:CHU de Rennes
    Full Title: Effet de la stimulation dopaminergique continue par pompe à apomorphine sur les fluctuations cognitives et psychiques des patients parkinsoniens: étude clinique et métabolique cérébrale par TEP au ...
    Medical condition: L’objectif thérapeutique principal dans la maladie de Parkinson est de contrôler les fluctuations motrices. Cependant des fluctuations non motrices (FNM) sont fréquemment observées et semblent corr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006684-22 Sponsor Protocol Number: 0600801 Start Date*: 2007-06-08
    Sponsor Name:CHU Toulouse
    Full Title: Evaluation des effets à long terme de l’amantadine chez le parkinsonien souffrant de dyskinésies induites par la lévodopa : Etude randomisée en double-insu versus placebo de l’arrêt d’une prescrip...
    Medical condition: maladie de parkinson
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    9.1 10013916 Dyskinesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001755-36 Sponsor Protocol Number: 2939117 Start Date*: 2006-08-09
    Sponsor Name:Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
    Full Title: Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodop...
    Medical condition: Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001175-32 Sponsor Protocol Number: BIA-91067-404 Start Date*: 2020-09-29
    Sponsor Name:Bial - Portela & Ca, S.A.
    Full Title: Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson’s disease patients with end-of-dose motor fluctuations and associated pain.
    Medical condition: Parkinson's disease patients with wearing-off motor fluctuations and associated pain.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) IT (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002949-38 Sponsor Protocol Number: CVL-751-PD-001 Start Date*: 2020-02-06
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEAS...
    Medical condition: Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) DE (Completed) FR (Completed) PL (Completed) ES (Ongoing) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004235-23 Sponsor Protocol Number: M15-737 Start Date*: 2020-11-09
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed) DE (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011093-15 Sponsor Protocol Number: 06173915 Start Date*: 2009-11-16
    Sponsor Name:Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
    Full Title: The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory.
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    12.0 10012271 Dementia Alzheimer's type LLT
    12.0 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000747-77 Sponsor Protocol Number: 283PD302 Start Date*: 2022-11-22
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122/DNL151 in Participants with Parkinson’s Disease and Pathogenic LRRK2 Variants
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 14:07:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA